Recently published in the journal Nature Medicine (1), results of exploratory research from the open-label phase III INTRIGUE clinical trial…
Nature Medicine
Developed in-house by VHIO-born spin-off company Peptomyc, OMO-103 is a mini-protein targeting the MYC oncogene which is found deregulated in…
Published ahead of print in Nature Medicine*, the final efficacy and safety results of the ROAR basket study led by…
